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ABSTRACT
On the basis of observations from dog models and human studies, we hypothesized that a low-dose (550 cGy),
single-exposure total body irradiation (TBI)–based regimen would result in improved survival when given to
adult patients with acute myelogenous leukemia (AML) who were undergoing unrelated donor bone marrow
transplantation in complete remission (CR). The regimen consisted of single exposure (550 cGy) of TBI given
at a high dose rate (30 cGy/min) and cyclophosphamide. Graft-versus-host disease prophylaxis consisted of
cyclosporine, methotrexate, and corticosteroids. Thirty-two consecutive adult patients (median age, 47 years)
with AML in CR (15 in CR 1 and 17 in CR>2) were treated. Sixteen patients (50%) were alive and in remission
at last follow-up (median, 2.2 years; range, 0.6-4.0 years). Kaplan-Meier estimates of overall and leukemia-free
survival at 3 years were 55%  14% (mean  SE) and 57%  14% in CR 1 patients and were both 39%  12%
in CR >2 patients. Transplant-related mortality was 13% for patients in CR 1 and 41% for those in CR >2.
Only 1 patient (3%) experienced fatal regimen-related organ toxicity, and only 1 had grade III or IV acute
graft-versus-host disease. Graft failure was not observed. Relapse occurred in 22% of patients. This low-dose
(550 cGy), single-exposure TBI-based regimen resulted in good survival and a low risk of fatal regimen-related
organ toxicity in adult patients with AML who underwent unrelated donor bone marrow transplantation in CR.
© 2004 American Society for Blood and Marrow Transplantation
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RNTRODUCTION
Data from the National Marrow Donor Program
NMDP) have shown that the overall survival at 3
ears of adult patients with acute myelogenous leuke-
ia (AML) who underwent unrelated donor (URD)
one marrow transplantation (BMT) between 1996
nd 2001 was 31% for patients in ﬁrst complete re-
ission (CR 1) and was 35% for patients in CR 2 [1].
he major cause of death for these patients was trans-
lant-related mortality (TRM). The risk of TRM after o
10RD transplantation for leukemia patients in CR was
3% to 62%, on the basis of data from the Interna-
ional Bone Marrow Transplant Registry (IBMTR)
2]. Most of these events occurred within the ﬁrst year
fter transplantation. The most common causes of
RM in this setting include regimen-related organ
oxicity (RROT), infection, and graft-versus-host dis-
ase (GVHD). In an NMDP study of more than 1400
atients with chronic myelogenous leukemia (CML),
ROT was the cause of death in 10.7% [3]. The risk
f fatal RROT is high in the URD setting, in part
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Because of the common use of more intensive condi-
ioning regimens designed to address the problem of
raft failure.
Alternative total body irradiation (TBI) dosing
trategies that reduce the intensity of the conditioning
egimen could decrease RROT and TRM without
ncreasing graft failure rates. Three variables deter-
ine the extent of myeloablation and lymphoablation
nd the toxicity after TBI exposure: total dose, dose
ate, and number of exposures. TBI administered at
0 cGy/min is capable of uniformly ablating canine
arrow for autologous recovery at a threshold total
ose of 600 cGy, whereas 920 cGy is necessary to
nsure lymphoablation for allogeneic engraftment
4,5]. However, higher total doses of TBI are associ-
ted with greater toxicity than lower total doses. Sin-
le-dose and fractionated TBI schemata have similar
yeloablative potentials when given at the same total
ose and dose rate; however, single-dose TBI results
n greater immunosuppression than fractionated sche-
ata [4,6]. Single-dose regimens are more immuno-
uppressive when given at a high dose rate in compar-
son to a low dose rate [7]. Conceptually, a low-total-
ose regimen could preserve myeloablative and
ymphoablative capabilities when administered in a
ingle dose and at a high dose rate but could reduce
oxicity by virtue of the low total dose administered.
ndeed, dog models using single-exposure TBI of 450
Gy given at high dose rates of 70 cGy/min resulted in
urable donor cell engraftment with minimal RROT
nd GVHD [7].
The University of Toronto transplant group dem-
nstrated the feasibility of a low-total-dose (500 cGy),
igh-dose-rate (median, 58 cGy/min) TBI-based reg-
men for related donor transplantation in humans [8].
e used a modiﬁed version of this strategy to develop
unique conditioning regimen for patients undergo-
ng HLA-matched sibling donor transplantation with
ow-dose (550 cGy) single-exposure TBI delivered at a
igh dose rate (30 cGy/min) along with cyclophos-
hamide and infusion of peripheral blood stem cells
9]. In 80 patients, this conditioning regimen resulted
n durable, complete donor cell (CDC) engraftment;
n absence of graft failure; and a low rate of fatal
ROT (2.5%). TRM observed through a minimum
ollow-up of 2 years was low with this regimen, oc-
urring in 7% and 19% of good- and poor-risk pa-
ients, respectively. In contrast, with conventional my-
loablative regimens, a recent report noted that the
isks of fatal RROT and TRM through 2 years were
4.8% and 21%, respectively [10].
We previously reported the outcomes of a heter-
geneous group of 54 patients undergoing URD
MT with this low-dose (550 cGy) TBI-based condi-
ioning regimen [11,12]. Fatal RROT was not ob-
erved, and the risk of serious RROT was low [8].
RM through at least 1 year of follow-up was rela- c
B&MTively low, at 24.1%, whereas the incidence of graft
ailure (9.3%) was similar to that reported by the
MDP after conventional myeloablative regimens
14%) [12,13]. Notably, none of the 20 patients with
ML experienced graft failure. Therefore, we hypoth-
sized that this low-dose (550 cGy), single-exposure,
igh-dose-rate TBI-based regimen would result in
mproved outcomes in patients with AML in CR un-
ergoing URD BMT.
ETHODS
atient Eligibility
Adult patients with AML in CR 1 or CR 2 were
ligible for treatment with this regimen. CR was de-
ned as 5% blasts by morphology in the bone mar-
ow (performed within 2 months of transplantation),
n absence of blasts in the peripheral blood, and an
bsence of chromosomal abnormalities in the marrow
if previously present). In addition, complete blood
ount must have demonstrated an absolute neutrophil
ount (ANC)1,000/L, platelets100,000/L, and
emoglobin 10 g/dL. Patients with AML in CR 1
ere considered candidates for URD BMT on the
asis of the presence of characteristics associated with
high risk for relapse when treated with conventional
hemotherapy alone. These characteristics included
oor-risk cytogenetic abnormalities, extramedullary
isease, peripheral blasts 100,000/L at presenta-
ion, requirement for reinduction, or secondary AML.
xclusion criteria included age 65 years, perfor-
ance status 2 (Eastern Cooperative Oncology
roup), left ventricular ejection fraction (LVEF)
40% of predicted, pulmonary function tests (diffu-
ion lung capacity of carbon monoxide, residual vol-
me, total lung capacity, or forced expiratory volume
n 1 second) 40% of predicted, serum creatinine
2.0 mg/dL, liver enzymes 5 times the upper limits
f normal, presence of an active acute or chronic
eep-seated infection, positive human immunodeﬁ-
iency virus I/II test, or a positive pregnancy test (if
emale). The Institutional Review Board of the Wash-
ngton University School of Medicine approved the
tudy, and each patient gave written, informed con-
ent. The patients described in this report represent a
ubset of 200 patients enrolled in an institutional
hase II study to determine the outcomes of patients
ith speciﬁc diagnoses undergoing URD BMT with
his regimen.
From the opening of the study in October 1997
hrough May 2002, 34 patients with AML in CR
eceived URD transplants at this institution, 32 of
hom were enrolled in this study and were treated
ith this conditioning regimen. Two patients were
onditioned with an alternative regimen (busulfan/
yclophosphamide) because of prior exposure to TBI
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3n one and insurance rejection of this research proto-
ol in the other. These 2 patients were not included in
his analysis. One patient was enrolled in this study
espite an LVEF of 20%, because it was believed that
onventional conditioning would present an unaccept-
bly high risk of mortality.
onor Selection
The NMDP facilitated selection of URDs. The
rimary criterion for donor selection was HLA com-
atibility, deﬁned as a 6/6 antigen match (at the A, B,
nd DRB1 loci) or a 5/6 antigen match (single-antigen
ismatch at the A, B, or DRB1 locus), with preference
or a 6/6 match. Secondary criteria for donor selection
ncluded preference for donors who were 10 of 10
atches (C and DQB1 loci in addition to the A, B, and
RB1 loci), had ABO compatibility, were cytomega-
ovirus (CMV) seronegative, and were male. Conﬁr-
atory typing on donors was performed at this insti-
ution. HLA class I antigens were serologically typed
ith low-resolution standard methods [14], whereas
RB1 and DQB1 typing was performed by high-
esolution polymerase chain reaction ampliﬁcation
ith single-stranded oligonucleotide probes [15]. Be-
inning in December 2000, class I antigens were also
yped with polymerase chain reaction ampliﬁcation
ith single-stranded oligonucleotide probes [15].
Bone marrow collection was coordinated through
he NMDP, performed at an NMDP-approved col-
ection center, and then transferred to this institution.
onor bone marrow cells were not T-cell depleted
ut were reduced of red blood cells or plasma as
ppropriate on the basis of recipient/donor ABO com-
atibility. Fresh bone marrow cells were transfused
nto the recipient on transplantation day 0, within 24
ours after the collection.
onditioning Regimen
Pretransplantation conditioning consisted of cy-
lophosphamide (60 mg/kg/d) given on days 3 and
2, followed by TBI administered in a single dose of
50 cGy on day 1. The mean dose rate was 32.7
Gy/min (range, 27.6-36.4 cGy/min). TBI was deliv-
red in parallel opposed lateral ﬁelds with 6-MeV
hotons by using Clinac 600 CD (Varian Medical
ystems, Alpharetta, GA). Patients were treated in a
itting position with a 300-cm source-to-midline dis-
ance. The point of dose prescription was a single
oint, midline in the body, at the level of the umbili-
us. A large Lucite plate (Lucite Intl Inc, Cordova,
N) was placed near the patient to enhance the skin
ose, and a tissue compensator was used to keep the
idline dose to the head and neck within 110% of the
rescribed dose. An ion chamber and diode placed on
ifferent parts of the body were used to ensure that the
easured and calculated doses were within acceptable p
12imits. The lungs and chest were not shielded from
adiation exposure.
VHD Prophylaxis, Evaluation, and Treatment
Cyclosporine for GVHD prophylaxis was started
n day2 as a continuous intravenous (IV) infusion of
mg/kg/d and was continued through day 100.
atients discharged before day 100 received a con-
inuous IV infusion at home. Drug levels were mea-
ured at least twice a week and were adjusted to
chieve a desired level of 200 to 400 ng/mL. At day
00, IV cyclosporine was switched to an oral dose of
.25 mg/kg every 12 hours. In patients without active
VHD, cyclosporine was tapered beginning at day
100 at a rate of approximately 5% per week. Addi-
ional GVHD prophylactic medications included
ethotrexate and corticosteroids. Methotrexate was
iven in doses of 10 mg/m2 IV on day 1 and 7.5
g/m2 on days 3 and 6. Methylprednisolone was
dministered at a dose of 1 mg/kg IV daily from day
7 until day 28. Methylprednisolone was switched
o an equivalent dose of oral prednisone when the
atient was able to swallow pills. In the absence of
VHD, prednisone was tapered off over 6 weeks
tarting approximately at day 28. Ten patients were
nrolled on a hydroxychloroquine (400 mg twice
aily) protocol and received the drug orally peritrans-
lantation for GVHD prophylaxis.
Acute GVHD was graded per Glucksberg et al.
16], and chronic GVHD was graded per Shulman et
l. [17]. Diagnoses of GVHD were based on clinical
anifestations and histology of biopsy samples of af-
ected tissues. Acute GVHD of stage II or greater of a
ingle organ (skin, gut, or liver) was treated with
ethylprednisolone at a dose of 2 mg/kg/d. Chronic
VHD was treated with cyclosporine and prednisone.
teroid-refractory acute and chronic GVHD was
reated with additional agents, according to the phy-
ician’s recommendations.
upportive Care
Prophylactic mesna and aggressive hydration were
iven to reduce the risk of hemorrhagic cystitis asso-
iated with cyclophosphamide. Granulocyte colony-
timulating factor was administered as a subcutaneous
njection of 10 g/kg/d beginning day 7 and was
iscontinued when the patient’s ANC exceeded
,500/L for 2 consecutive blood draws after the
NC nadir. Single-donor irradiated platelet compo-
ents were transfused for a platelet count 10,000/
L, and 2 units of packed red blood cells were trans-
used for hemoglobin 8 g/dL.
Acyclovir (400 mg 3 times daily), itraconazole (200
g twice daily), and trimethoprim/sulfamethoxazole
160/800 mg twice weekly) were given orally as pro-
hylaxis against pathogens to all patients during re-
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TBI, Unrelated Donor Transplantation, Acute Leukemia
Beipt of immunosuppressive therapy. During the ini-
ial hospitalization, prophylactic antibacterial agents
ciproﬂoxacin and rifampin) were given from day 3
ntil the initial occurrence of fever (temperature
38.3°C) or resolution of neutropenia, whichever oc-
urred ﬁrst. Initial empiric therapy of febrile neutro-
enia consisted of imipenem/cilastatin or cefepime,
ith subsequent addition of vancomycin for suspected
atheter-related infections or amphotericin B for sus-
ected fungal infections. Culture-proven bacteremia,
epsis syndrome, or tissue infection was treated with a
4-day course of appropriate IV antimicrobial agents.
urveillance blood testing for CMV was performed
very 2 weeks by routine viral and shell vial culture of
uffy-coat specimens until day150. A positive CMV
est result without manifestations of CMV disease was
reated with ganciclovir 5 mg/kg/d IV for 21 days.
MV disease was treated with ganciclovir 5 mg/kg
wice daily for 21 days and with immune globulin 500
g/kg IV every other day for 7 doses.
valuation, End Points, and Statistics
Posttransplantation evaluations were performed
n approximately days 30, 100, and 180; year 1;
nd yearly thereafter. Each evaluation included assess-
ent of survival status (alive or dead), disease status
CR or relapse), marrow chimerism, RROT, TRM,
nd GVHD (grade). Chimerism was assessed by using
ariable number tandem repeat probes [9,18,19]. The
ensitivity of this method was 1% to 5%.
The end points of the study were leukemia-free
LFS) and overall survival (OS), RROT, TRM,
VHD, and donor cell engraftment. Both LFS and
S were assessed by the Kaplan-Meier (KM) tech-
ique and were determined from the day of transplan-
ation [20]. Relapsed AML was deﬁned as morpho-
ogic evidence of AML in the marrow, peripheral
lood, or tissue occurring at any single posttransplan-
ation evaluation. Patients were censored for LFS if
hey were alive and in remission at last follow-up.
atients were censored for OS if they were alive at last
ollow-up. Follow-up was through January 1, 2003.
nalysis was performed with StatView (version 4.5;
bacus Concepts, Inc., Berkeley, CA).
RROT was graded with the National Cancer In-
titute (NCI) criteria for BMT studies. According to
hese criteria, grade 0 indicates no organ toxicity,
rade 5 indicates fatal toxicity, and grades 1 to 4
ndicate increasing levels of toxicity [21]. Idiopathic
nterstitial pneumonitis was deﬁned as bilateral inter-
titial pulmonary inﬁltrates associated with shortness
f breath and hypoxemia occurring after transplanta-
ion in which no infectious etiology could be deﬁned
y culture of the pulmonary tissue/secretions or
lood. Cases in which pulmonary inﬁltrates developed
n association with sepsis (fever with hypotension) in e
B&MThe absence of positive cultures were scored as infec-
ious pneumonias and were assumed to be due to a
acterial cause. TRM was deﬁned as death from all
auses after transplantation, excluding deaths due to
elapsed disease. Patients who died before neutrophil
ngraftment without evidence of GVHD were not
valuable for acute GVHD. Patients who experienced
rimary graft failure were also not evaluable for acute
VHD. Patients who died or relapsed before day
100 were not evaluable for chronic GVHD.
Engraftment was deﬁned as CDC engraftment if
arrow cells were only of donor origin (1% recip-
ent) by variable number tandem repeat probes or as
ixed if marrow cells were of donor and host origin.
rimary graft failure was deﬁned as persistent neutro-
enia (ANC 500/L) through day 30 with no
vidence of engraftment of donor cells. Secondary
raft failure was deﬁned as an initial engraftment of
eutrophils (postnadir ANC 1500/L for 2 consec-
tive blood draws) of donor origin followed by the
evelopment of unexplained neutropenia (ANC
500/L for at least 3 consecutive blood draws) in
ssociation with evidence of loss of donor cells. Pa-
ients with relapsed AML were not evaluable for en-
raftment or graft failure at the time of or after re-
apse.
ESULTS
atient and Bone Marrow Characteristics
Thirty-two consecutive patients were enrolled in
his study, and all received the conditioning regimen
ollowed by URD BMT. Patient characteristics are
isted in Table 1. The median patient age at the time
f transplantation was 47 years (range, 32-60 years).
en patients were at least 50 years of age. At trans-
lantation, 15, 15, and 2 patients had AML in CR 1,
R 2, and CR 3, respectively. Primary reasons for
erforming URD BMT in CR 1 were adverse cyto-
enetics (9 patients), extramedullary involvement (2
atients), high white blood cell count (100000/L)
n presentation (1 patient), requirement for second
nduction (1 patient), and secondary AML (1 patient).
ne patient underwent URD BMT in CR 1 because
f the presence of t(9;11), which was associated with a
oor prognosis, as described in the literature at that
ime [22,23]. Six patients with AML in CR 1 had
ultiple high-risk characteristics. The median fol-
ow-up for the 16 living patients was 791 days (range,
05-1475 days). The median numbers of CD34 and
D3 bone marrow cells given were 2.95  106
range, 1.22-6.90  106) and 4.64  107 (range, 0.83-
.23  107) cells per kilogram, respectively.
egimen-Related Organ Toxicity
A maximum organ toxicity of NCI grade 2 was
xperienced by 25 (78%) of 32 patients (Table 2).
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3nly 1 patient (3%) experienced NCI grade 5 (fatal)
rgan toxicity. This patient began the conditioning
egimen with an LVEF of 20% and died on day 5
ecause of cardiac toxicity from ventricular ﬁbrilla-
ion/cardiac arrest. Two patients (6%) experienced
rade 4 (life-threatening) organ toxicity. The previ-
usly discussed patient with fatal cardiac toxicity also
eveloped grade 4 liver toxicity due to veno-occlusive
isease. One other patient experienced grade 4 blad-
er toxicity due to hemorrhagic cystitis, which re-
uired instillation of intravesical formalin. Only 1 pa-
ient developed idiopathic interstitial pneumonitis
grade 2 pulmonary toxicity). This patient subse-
uently also experienced obliterative bronchitis on day
617 but remained alive at last follow-up (day
1382). Serious (grade 3) central nervous system
CNS) toxicity occurred in 2 patients and was due to
yclosporine. One of these patients experienced sei-
ures, which resolved on discontinuation of cyclospor-
ne. The other patient experienced CNS hemorrhage
nd died of an infection-related TRM (CMV pneu-
onia) before resolution of CNS symptoms.
able 1. Patient Characteristics
Characteristic Al
ge, y, median (range)
ex (male/female)
dverse cytogenetics*
econdary AML
equired second induction
xtramedullary involvement
iagnosis to transplantation mo, median
(range)
R duration before relapse, mo, median (range)
onor sex (male/female)
LA A, B, DRB1
6/6 match
5/6 match (A or B mismatch)
5/6 match (DRB1 mismatch)
/R** CMV status
Negative/negative
D and/or R positive
Adverse cytogenetics in these patients included 7, t(6;9), 11q23
*D indicates donor; R, recipient; NA, not applicable.
able 2. Regimen-Related Organ Toxicity
Organ
NCl Toxicity Grade*
0 1 2 3 4 5 (Fatal)
ulmonary 31 0 1 0 0 0
NS 28 0 2 2 0 0
enal 20 7 3 2 0 0
ral mucosa 9 11 10 2 0 0
ladder 29 1 0 1 1 0
iver 15 11 5 0 1 0
ardiac 29 0 1 1 0 1
NS indicates central nervous system.
GNCl criteria for BMT studies [18].
14nfection
The number of patients who experienced only
ram-positive, only gram-negative, or both bactere-
ias within the ﬁrst 100 days after transplantation was
(28%), 2 (6%), and 2 (6%), respectively. Fifteen
47%) patients developed CMV viremia, whereas 4
atients (13%) developed CMV pneumonia. Of the
atter, 2 died of CMV pneumonia, 1 died of culture-
egative (presumed bacterial etiology) pneumonia,
nd 1 died of relapsed disease. Only 1 patient devel-
ped a serious fungal infection (in the context of
mmunosuppressive therapy for extensive chronic
VHD), which was believed to be aspergillus pneu-
onia on the basis of clinical manifestation and re-
ponse to antifungal treatment. This patient also de-
eloped toxoplasmosis but recovered from both
nfections.
Ten (31%) patients developed infectious pneumo-
ias; the etiologies were bacterial, viral, fungal, and
ulture negative in 3, 4, 1, and 2 patients, respectively.
he median day of onset of infectious pneumonia was
19 (range, 16-538). One case of pneumonia occurred
n association with active acute GVHD, whereas 4
ccurred with active chronic GVHD. Of the 10 pa-
ients who developed infectious pneumonias, 5 died
efore resolution and 5 recovered.
Overall, the primary cause of death was infection
n 7 patients. Five deaths were due to a bacterial
nfection (pneumonia in 3 and sepsis in 2), and 2
eaths were due to viral infection (both pneumonias).
raft-versus-Host Disease
Of the 31 patients who engrafted donor bone
arrow cells and were therefore evaluable for
 32) CR 1 (n  15) CR >2 (n  17)
-60) 47 (32-59) 47 (37-60)
2 5/10 5/12
9 2
3 0
3 2
2 1
9) 6 (4-12) 19 (9-79)
NA 14 (3-37)
13/2 10/7
14 15
1 1
0 1
6 4
9 13
ing t(9;11)], and complex (3 or more different abnormalities) [19].l CR (n
47 (32
10/2
11
3
5
3
12 (4-7
NA
23/9
29
2
1
10
22
[excludVHD, 17 (55%) did not experience (grade 0) acute
G
g
(
e
r
a
t
G
c
K
c
s
E
r
t
b
p

(
1
H
S
a
1
d
i

n
D
a
m
h
w
t
d
S
w
u
(
t
O
f
p
e
w
w
o
(
t
T
1
o
b
p
(
w
C
t
c
F
O
T
R
T
F
C
o
F
C
TBI, Unrelated Donor Transplantation, Acute Leukemia
BVHD. The number of patients who experienced
rade I, II, and III acute GVHD was 8 (26%), 5
16%), and 1 (3%), respectively. No patients experi-
nced grade IV acute GVHD. The KM cumulative
isks for developing grade I to IV or grades III to IV
cute GVHD at 100 days were 46% and 3%, respec-
ively. Twenty-six patients were evaluable for chronic
VHD; limited and extensive chronic GVHD oc-
urred in 2 (8%) and 14 (54%) patients, respectively.
M cumulative risks for developing any or extensive
hronic GVHD at 2 years were 76% and 67%, re-
pectively.
ngraftment and Chimerism
Graft failure did not occur with this conditioning
egimen. At day 30, 27 (96%) of 28 evaluable pa-
ients demonstrated 100% CDC chimerism in the
one marrow. The percentages (fraction) of evaluable
atients who demonstrated CDC chimerism at days
100 and 180 and years 1, 2, and 3 were 88%
21/24), 91% (21/23), 94% (15/16), 100% (7/7), and
00% (3/3), respectively.
ematologic Recovery, Febrile Days, and Hospital
tay
The median times to recovery of ANC 500/L
nd platelets 20,000/L (7 days unsupported) were
3 days (range, 11-21 days) and 21 days (range, 15-35
ays), respectively. During the initial BMT hospital-
zation, the median number of febrile (temperature
38.3°C) days was 0 (range, 0-7), whereas the median
umber of days on IV antibiotics was 8 (range, 0-28).
uring this interval, 19 patients remained afebrile,
nd 9 patients did not require IV antibiotics. The
edian length of hospital stay during the initial BMT
ospitalization was 19 days (range, 10-32 days),
hereas the median number of hospitalized days from
he beginning of the conditioning regimen through
ay 100 was 25 (range, 10-64).
urvival, TRM, and Relapse
The median follow-up for the surviving patients
as 791 days (range, 205-1475 days). At last follow-
p, 16 patients were alive and in CR, including 9
able 3. Primary Causes of Death
Cause of Death
All CR
(n  32)
CR 1
(n  15)
CR >2
(n  17)
elapse 7 4 3
RM (total) 9 2 7
Organ toxicity 1 0 1
GVHD 1 0 1
Infection 7 2 5
Bacterial 5 1 4
Viral 2 1 1n
B&MT60%) patients with AML in CR 1 and 7 (41%) pa-
ients with AML in CR 2. Eastern Cooperative
ncology Group performance status at last evaluation
or the living patients was 0 and 1 to 2 in 12 and 4
atients, respectively. Of the living patients, 8 had no
vidence of chronic GVHD at last follow-up, and 6
ere completely off immunosuppression.
The primary causes of death of the 16 patients
ho died are listed in Table 3. Death due to TRM
ccurred in 9 patients (28%) overall, including 2
13%) patients with AML in CR 1 and 7 (41%) pa-
ients with AML in CR 2. The primary causes of
RM were infection, GVHD, and organ toxicity in 7,
, and 1 patients, respectively. Of all TRM events, 4
ccurred in the context of GVHD. TRM occurred
efore day 100 in 4 patients and before year 1 in 8
atients. Relapse of AML after BMT occurred in 7
22%) patients overall, including 4 (27%) patients
ith AML in CR 1 and 3 (18%) patients with AML in
R 2. All 7 patients whose disease relapsed after
ransplantation died. Of the 11 patients with adverse
ytogenetics, 3 (27%) relapsed after transplantation.
KM estimates for OS and LFS are depicted in
igures 1 and 2. For the patients with AML in CR 1,
S and LFS at 3 years were 55% 14% (mean SE)
igure 1. Overall survival (OS) of patients with AML in CR 1 and
R 2, as determined by the KM technique. The median number
f follow-up days was 791 (range, 205-1475).
igure 2. Leukemia-free survival (LFS) of patients with AML in
R 1 and CR2, as determined by the KM technique. The median
umber of follow-up days was 791 (range, 205-1475).
315
a
A
3
D
s
w
w
m
K
C
c
o
p
i
i
w
C
T
(
s
i
1
p
r
t
y
p
t
t
a
t
r
(
e
d
a
G
w

p
C
r
p
s
d
a
3
o
p
t
a
T
w
r
t
A
m
t
a
D
w
l
p
l
e
r
U
w
r
t
u
i
T
c
l
o
R
s
s
p
f
o
w
i
d
t
9
p
r
R
T
r
a
ﬁ
s
l
w
R
l
o
c
r
a
v
w
F
d
C. Hallemeier et al.
3nd 57%  14%, respectively. For the patients with
ML in CR 2, OS and LFS at 3 years were both
9%  12%.
ISCUSSION
We hypothesized that this low-dose (550 cGy)
ingle-exposure high-dose-rate TBI-based regimen
ould result in improved outcomes in adult patients
ith AML undergoing URD BMT in CR. With a
edian follow-up of 2.2 years in living patients, the
M estimates of 3-year OS for patients in CR 1 and
R 2 were 55% and 39%, respectively. These out-
omes compare favorably with data from the NMDP
n adult patients with AML who underwent trans-
lantation in CR from 1996 to 2001 [1]. In this report,
n which primarily conventional TBI-based condition-
ng regimens were used, the 3-year OS for patients
ho underwent transplantation in CR 1 (n 215) and
R 2 (n  266) were 31% and 35%, respectively.
he Fred Hutchinson Cancer Research Center
FHCRC) recently published the most comprehensive
ingle-institutional experience on patients with AML
n CR undergoing URD BMT after conditioning with
320- to 1575-cGy fractionated TBI and cyclophos-
hamide [24]. To the authors’ knowledge, these data
epresent the best LFS outcomes published for pa-
ients with AML in CR undergoing URD BMT. Five-
ear LFS for CR 1 (n  16) and CR 2 (n  40)
atients was 50%  12% and 28%  8%, respec-
ively, with a median follow-up of 2.9 years. In both
his study and ours, all patients with AML in CR 1 had
dverse prognostic features for relapse. However, pa-
ients in our study were older (median age, 47 years;
ange, 32-60 years) than those in the FHCRC report
median age, 29 years; range, 1-55 years). The adverse
ffect of advancing age on OS after conventional con-
itioning and URD BMT was clearly demonstrated in
report of 1400 patients with CML, in which Mc-
lave et al. [3] observed that the relative risk of death
as 1.45 for patients 35 years of age versus those
35 years. However, in our study, the 3-year LFS for
atients with AML who underwent transplantation in
R 1 and CR 2 was 57%  14% and 39%  12%,
espectively. It is interesting to note that the LFS of
atients with AML in CR 1 treated in this study was
imilar to that reported for patients with the same
iagnosis given conventional TBI-based conditioning
nd related donor BMT [25]. In the latter report, the
-year LFS was 55%. Thus, despite the older age of
ur patient population and the presence of adverse
rognostic features in all patients, this novel condi-
ioning regimen resulted in relatively good survival for
dult patients with AML undergoing URD BMT.
hese data should be conﬁrmed in more patients and
ith longer follow-up. Comparisons of these data with w
16eports in the literature must be interpreted with cau-
ion because of confounding variables that may exist.
The improved survival outcomes of patients with
ML in CR undergoing URD BMT with this regi-
en could in part be due to a reduction in TRM. In
his study, the TRM was 28% overall and was 13%
nd 41% in patients in CR 1 and CR2, respectively.
ata from the IBMTR indicated that the risk of TRM
as 53% in patients undergoing URD BMT for early
eukemia (acute leukemia in CR 1 or CML in chronic
hase) and was 62% in patients with intermediate
eukemia (acute leukemia in CR 2 or CML in accel-
rated phase) [5]. In a report from the FHCRC, the
isk of TRM after conventional conditioning and
RD BMT for patients with AML in CR 1 and CR 2
as 31% and 49%, respectively [24]. In fact, the TRM
ate observed with our regimen (28%) was similar to
hat seen in a recent report (23%) of 52 patients
ndergoing URD BMT with a nonmyeloablative reg-
men that used 200 cGy of TBI and ﬂudarabine [34].
he relatively lower risk of TRM observed in patients
onditioned with our low-dose TBI-based regimen is
ikely due to the very low risk of fatal RROT, which
ccurred in only 1 patient (3%). The risk of fatal
ROT with this conditioning regimen in the URD
etting was nearly identical to the rate that we ob-
erved with this regimen in the related donor trans-
lant setting (2.5% in 80 patients) [9]. In contrast, data
rom the NMDP and reported by McGlave et al. [3]
n more than 1000 patients undergoing URD BMT
ith conventional TBI-based regimens indicate an
ncidence of fatal RROT of 10.7%, with most of these
eaths occurring because of respiratory and hepatic
oxicity [5]. Similar rates of fatal RROT (ranging from
% to 12%) have been observed in other large patient
opulations with use of conventional conditioning
egimens for URD BMT [26-28]. The low risk of fatal
ROT that we observed with this low-dose (550 cGy)
BI-based conditioning regimen is probably an accu-
ate reﬂection of the true risk of this outcome, because
lmost all of these adverse events occurred within the
rst 100 days after transplantation and because all
urviving patients in this study had a minimum fol-
ow-up of more than 200 days. Additional follow-up
ill be necessary to determine whether late-onset
ROT events may occur that could affect the cumu-
ative risk of TRM, although the occurrence of late-
nset fatal RROT seems unlikely.
An important concern with any reduced-intensity
onditioning regimen is that the decreased regimen-
elated morbidity and mortality could inadvertently be
ssociated with less effective disease eradication. Pre-
ious randomized trials have proven this to be the case
hen comparing standard versus higher-dose TBI.
or patients with AML in CR 1 undergoing related
onor transplantation, using a conditioning regimen
ith 1200 versus 1575 cGy of TBI resulted in a lower
p
[
w
o
w
w
o
s
r
i
B
S
a
l
l
u
s
p
p
c
d
f
U
b
w
a
B
p
u
s
i
o
t
t
u
t
a
w
c
f
m
s
o
h
t
a
T
d
s
b
3
e
i
C
T
w
p
a
p
s
w
i
o
f
s
t
e
p
t
a
e
o
b
p
3
t
c
n
a
T
T
r
o
s
o
t
d
a
u
G
r
B
s
e
p
I
w
a
c
w
p
a
o
U
H
u
i
s
u
m
TBI, Unrelated Donor Transplantation, Acute Leukemia
Brobability of TRM but a higher probability of relapse
29]. Thus, if an improvement in OS is to be achieved
ith reduced-intensity conditioning regimens, the risk
f relapse of leukemia must not exceed that observed
ith conventional regimens. For patients with AML
ho underwent transplantation in CR 1 and CR2 in
ur study, the relapse risks were 27% and 18%, re-
pectively. These relapse risks are comparable to the
elapse risks of 19% and 23% for patients with AML
n CR 1 and CR 2, respectively, undergoing URD
MT after conventional conditioning regimens [24].
imilarly, IBMTR data indicated that the relapse risk
fter URD BMT was 13% for patients with early
eukemia and was 25% for patients with intermediate
eukemia [5]. Furthermore, we reported that patients
ndergoing related donor transplantation with this
ame low-dose TBI-based conditioning regimen ex-
erienced relapse risks of 15% and 45% in good- and
oor-risk patients, respectively [9]; these rates are
omparable to those reported with conventional con-
itioning regimens [30-33]. Given that the median
ollow-up for patients with AML in CR undergoing
RD BMT was only 2.2 years, longer follow-up will
e necessary to conﬁrm that the relapse rates observed
ith this low-dose TBI-based conditioning regimen
re similar to those with conventional regimens.
Graft failure is a frequent problem in the URD
MT setting. An NMDP report on more than 5000
atients undergoing URD BMT observed a graft fail-
re incidence of 14% [13]. Historically, a common
trategy to reduce the risk of graft failure has been to
ncrease the immunosuppression in the patient by use
f high doses of TBI, the addition of other chemo-
herapy, anti–T-cell antibodies, or a combination of
hese. There has been a recent surge in interest for
sing a nonmyeloablative regimen in the URD setting
o reduce RROT. However, the use of nonmyelo-
blative regimens in this setting has been associated
ith an increased risk of graft failure and early mixed
himerism [34,35]. To address the problem of graft
ailure in the URD setting, we chose this novel regi-
en on the basis of animal models, which demon-
trated that higher rates of donor cell engraftment
ccurred with single (versus fractionated) TBI given at
igh (versus low) dose rates [7]. Such models showed
hat relatively low total doses of TBI (450 cGy) were
dequate to ensure engraftment of donor cells if the
BI was administered as a single dose and at a high
ose rate (70 cGy/min). With our low-dose (550 cGy),
ingle-exposure, high-dose-rate (30 cGy/min) TBI-
ased regimen, graft failure did not occur in any of the
2 patients with AML treated in this study. Indeed,
ngraftment was prompt and complete with this reg-
men: 27 (96%) of 28 evaluable patients experienced
DC chimerism at day 30 after transplantation.
hese data compare favorably with those reported
ith nonmyeloablative conditioning regimens; com- a
B&MTlete donor T-cell engraftment at day 30 was 27%
nd 50% with 200 cGy of TBI/ﬂudarabine and cyclo-
hosphamide/ﬂudarabine conditioning regimens, re-
pectively [34,35]. Although the risk of graft failure
ith our low-dose (550 cGy), high-dose-rate regimen
s low in patients with AML, we observed a higher risk
f graft failure in patients with CML (16%). There-
ore, our novel preparative regimen would best fall
omewhere between nonmyeloablative and conven-
ional fully myeloablative regimens in terms of my-
loablative potential, but the high rate of early, com-
lete engraftment observed is more characteristic of
hose seen with fully myeloablative regimens. Early
nd complete donor cell engraftment (versus delayed
ngraftment) may be important, because achievement
f donor cell engraftment has been demonstrated to
e correlated with disease regression and thus may
rovide improved graft-versus-leukemia activity [35-
7]. The rate of durable donor cell engraftment and
he risk of graft failure with this low-dose TBI-based
onditioning regimen should be conﬁrmed with larger
umbers of patients with AML in CR.
The most frequent life-threatening complication
fter URD BMT is infection, which accounts for most
RM events. As expected, the most frequent cause of
RM in our patient population was infection (bacte-
ial in 5 and viral in 2). Also, 10 patients (31%) devel-
ped infectious pneumonias. Half of these patients
urvived this event. The incidence of pneumonia in
ur patient population was similar to that reported in
he literature for URD BMT patients and reﬂects the
egree of intense immunosuppression and the associ-
ted high risk of infection experienced by all patients
ndergoing URD BMT [26].
We observed a low incidence of severe acute
VHD in this population given this conditioning
egimen, followed by non–T cell–depleted URD
MT with cyclosporine, methotrexate, and cortico-
teroids as GVHD prophylaxis. Only 1 patient (3%)
xperienced grade III to IV acute GVHD, and 17
atients (55%) did not experience any acute GVHD.
n contrast, the FHCRC noted that 41% of patients
ith AML experienced grades III to IV acute GVHD
fter conditioning with 1320 to 1575 cGy of TBI and
yclophosphamide and unmanipulated URD BMT,
ith cyclosporine and methotrexate for GVHD pro-
hylaxis [24]. In fact, the incidence of grades III-IV
cute GVHD (3%) observed in patients treated with
ur low-dose (550 cGy) TBI-based regimen in the
RD setting is similar to that which we observed after
LA-matched related donor transplantation (8%) by
sing the same conditioning regimen with cyclospor-
ne alone [9]. The explanation for the low risk of
evere acute GVHD that we observed in this study is
nclear, but it is likely a reﬂection of close allele-level
atching in most donor/recipient pairs (91% matched
t the A, B, and DRB1 loci) and is perhaps due to the
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3se of triple-agent immunosuppression. However, this
ow risk could also be a result of the low total dose
550 cGy) of TBI administered, because murine mod-
ls have demonstrated that lower TBI doses (as op-
osed to higher doses) were associated with decreased
ut injury, inﬂammatory cytokine levels, and acute
VHD incidence [38,39]. Also, prior randomized tri-
ls in humans have observed a lower incidence of
VHD after conditioning with 1200 versus 1575 cGy
f TBI [31]. A randomized study is needed to deter-
ine whether the risk of developing acute GVHD is
ecreased with the conditioning regimen used in our
tudy.
Over the same time interval, 18 patients with re-
ractory, persistent AML treated at our institution
ere conditioned with 550 cGy of single-exposure
BI and cyclophosphamide followed by URD BMT
40]. The median follow-up of these patients was 2
ears. At last follow-up, 17 patients had died (12 be-
ause of relapse and 5 because of TRM), and only 1
atient remained alive but with relapsed disease. KM
stimates of OS and LFS at 3 years were 5% and 0%.
hus, patients with refractory, persistent AML at the
ime of URD BMT require increased regimen inten-
ity to ensure more effective disease eradication.
In conclusion, our low-dose (550 cGy), high-dose-
ate, single-exposure TBI-based conditioning regimen
esulted in good outcomes in adult patients (median
ge, 47 years) with AML in CR undergoing URD
MT. This novel conditioning regimen seems have a
ow risk of TRM and fatal RROT similar to that
bserved with a nonmyeloablative regimen, but it re-
ains the disease control and donor cell engraftment
ate observed with conventional TBI-based regimens.
his reduced-intensity conditioning regimen warrants
urther studies in patients undergoing URD BMT.
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